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    INTRODUCTION 
           
Diabetes  mellitus  is  a  condition  in  which  there  is  a  chronically  
raised  blood  glucose  concentration.  It  is  caused  by  an  absolute  or  
relative  lack  of  the hormone  insulin,  i.e. insulin  is  not  being  produced  
from  the  pancreas  or  there  is  insufficient  production  of  insulin  or  
impaired  insulin  action  for  the   needs. 
The  two  main  types  of  diabetes  are  Type  1  which  presents  mainly  
in childhood  and  early  adult  life  and  accounts  for  about  20%  of  cases  in 
Europe  and  North  America.  It  is  thought  to  be  caused  by  autoimmune 
destruction  of  insulin  producing  islet  cells  of  pancreas. 
Type  2  Diabetes  usually  starts  in  middle  age  or  in  the  elderly.  It  
is  more  common  accounting  for  80%  of  cases.  It  is  due  to  either  
impaired  insulin  secretion  or resistance  to  the  action  of  insulin  at its  
targets  cells.  Most  of  these  patients  are  obese. 
One  of  the  most  important  clinical  features  of  diabetes  is  its 
association  with  chronic  tissue  complications  that  occurs  after several  
years  of  diabetes  and  affect  both  small  blood  vessel  (microangiopathy)  in  
the  eye,  kidney  and  nerves  and  large  vessels. The  frequency  of  arterial  
disease  (atherosclerosis  or  microangiopathy)  is  also  markedly  increased.  
Microangiopathy  is thought  to  be  related  to  the  duration  and  severity  of  
hyperglycemia. 
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Diabetic  retinopathy  is  a  serious  complication  of  diabetes  mellitus  
and  it  is considered  as  a  major  cause  of  blindness  in  working  population.  
Its  pathogenesis  is  complicated  and  it  is  related  to  many  factors,  but  
many  groups  have  described the  role  of  inflammatory  markers  in  the  
development  of  diabetic  retinopathy. 
The  WBC  and  its  subtypes  Neutrophil  lymphocyte  ratio,  Monocyte  
lymphocyte ratio  and  platelet  lymphocyte  ratio  are  all  novel  markers  of  
inflammation. Till  date,  only  few  articles  have  studied  the  relationship  
between  the  occurrence  of diabetic  microvascular  complication  and  the  
markers  of  inflammation. 
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                                   AIM OF STUDY 
        
The  aim  of  my  study  is  to  evaluate  the  association  between  
Diabetic  retinopathy  and  the  Neutrophil    Lymphocyte  ratio,  Monocyte    
Lymphocyte  Ratio  and  the  Platelet    Lymphocyte Ratio. 
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                     REVIEW  OF  LITERATURE 
 
DIABETES MELLLITUS 
 
Diabetes  mellitus  is  a  metabolic  disorder  involving  carbohydrate,  
protein  and  fat  metabolism  resulting  from  absolute  or  relative insulin  
deficiency  and  resulting  in  chronic  hyperglycemia  manifesting  with  its  
microvascular  and  macrovascular  complications.  In  fact  diabetes  can  have  
a  long  variable  asymptomatic  period  of  5  years  to  15 years  and  may  be  
diagnosed  for  the  first  time  because  of  its comorbities  or  complications.  
The  long  term  effects  of  diabetes  include  damage,  dysfunction  and  
failure  of various  other  organs  which  includes  progressive  development  of  
retinopathy with  potential  blindness,  nephropathy  that  may  lead  to  renal  
failure, neuropathy  with  risk  of  foot  ulcers,  amputation,  charcot  joints  and  
features of  autonomic  dysfunction  including  sexual  dysfunction.  People  
with  diabetes are  at  increased  risk  of  macrovascular  complications  like  
cardiovascular, peripheral  vascular  and  cerebrovascular  diseases. 
EPIDEMIOLOGY 
According  to  the  data  collected  by  World  Health  Organisation  
(WHO)  in  2016,  it  is  estimated  that  around  422  million  of  adults  are  
living  with  diabetes  mellitus.  It  is  mainly  due  to  increase  in  risk  factors  
for  type  2  diabetes  mellitus  notably  sedentary  lifestyle,  obesity  and  
increased  longevity. 
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TYPE 1 DIABETES 
Type  1  diabetes  may  present  at  any  age,  but  most  typically  
presents  in  early life with  peak  incidence  around  the  time  of  puberty.  Its  
incidence  varies  from  50 -100 fold  around  the  world,  with  the  highest  
among  the  Northern  Europe  and  in individuals  of  European  extraction.  
Both  the  sexes  are  equally  affected  in childhood,  but  men  are  more  
commonly affected in early adult life. This distinction between type 1 and 
type 2  varies  in  later  life  and  thus  true  life incidence  is  unkown.  
According  to  DIAMOND  study,  Finland  has  the  maximum number  of  
patients  with  Diabetes. 
TYPE 2 DIABETES 
The  World  Health  Organisation  estimated  that  9%  of  the   
population suffered  from  Diabetes  in  2014,  over  90%  of  them  had  type 2  
Diabetes.  Moreover type 2  diabetes  caused  5 million  deaths  per  year , 
mostly  from  cardiovascular disease,  and  type 2  diabetes  is  expected  to  
become  7th  leading  cause  of  death globally  by  2030.  Type 2  diabetes  is  
strongly  associated  with  obesity  and  as  such the  major  burden  is  now  in  
the  middle  income  and  developing  countries  where urbanization  and  
recent  affluence  has  rapidly  changed  the  lifestyle. 
The  large  population  of  the  Western  pacific  contributed  most  to  
the  absolute numbers,  while  the  %  prevalence  is  highest  in  the  Middle  
east  and  North  Africa. The  larger  number  of  diabetics  are  in  the  40-59 
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age  groups  (132 million in 2010) which  are  expected  to  rise  further.  By  
2030,  there  will  be  more  diabetic population  in  the  60  to  79  age  groups  
(196 million).  
GESTATIONAL DIABETES 
GDM  is  common  in  many  population  including  Asian  Indians.  
Pregnant  women should  be  tested  for  GDM  at  24  weeks  to  28  weeks  of  
gestation.  Gestational diabetes  is  a  prediabetic  state  with  an  increased  risk  
of  development  of  the disorder  in  subsequent  pregnancies,  in  60  to  90%.  
It  is  also  known  that  women with  GDM  have  a  high  risk  upto  30%  of  
developing  diabetes  within  7  10  years of  index  pregnancy. 
PREVALENCE IN INDIA 
The  prevalence  of  diabetes  in  India  in  1970s  was  2.3%  in  urban  
and  1.5%  in rural  areas  as  shown  by  study  conducted  by  ICMR.  In  
2000s  the  prevalence gradually  increased.  India  which  has  a  large  pool  of  
pre diabetics  shows  rapid conversion  of  these  high  risk  subjects  to  
diabetes. The  Indian  Diabetic  Prevention Programme  1 (IDPP  1)  has  
shown  an  annual  incidence  of  approximately  18% among  subjects  with  
IGT. 
National  studies  or  population  based  studies  on  diabetic  
complications  are  sparse  in  India.  A  few  population  based  studies  
indicate  that  the  prevalence  of  retinopathy  to  be  27%  and  overt  
nephropathy  is  2.2%.  Peripheral  vascular  disease is  prevalent  in  6.3%,  
peripheral  neuropathy  in  25%  and  coronary  artery  disease  is seen  in  21%. 
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The  major  contributory  factors  for  the  prevalence  of  the 
complications  are: delayed diagnosis  of  diabetes,  inadequate  control  of  
diabetes,  hypertension  and  lack  of awareness  about  the  disease  among  
majority  of  the  public. 
Diabetic  retinopathy  is  one  of  the  most  common  complication  and 
leading  cause  of  preventable  blindness  among  the  working population.  It  
is  estimated  that  around  93  million   have  diabetic retinopathy  of  whom  
17  million  (18%)  have  proliferative  diabetic retinopathy,  21  million  (23%)  
have  diabetic  macular  edema,  and  28  million  (20%)  have  vision  
threatening  diabetic  retinopathy. 
WHO CRITERIA: 
Criteria  for  Diabetes  diagnosis: 4 options 
 Fasting  plasma  glucose   126 mg/dl (7.0mmol/L) 
Fasting  is  defined  as  no  caloric  intake  for    8 hours. 
 2  hour  post  prandial  glucose   200mg/dl  (11.1mmol/L)  during  
OGTT (75g) 
Using  a  glucose  load  containing  the  equivalent  of  75g  anhydrous  
glucose dissolved  in  water. 
 HbA1C   6.5%  (48mmol/L) 
 Random  plasma  glucose    200mg/dl  (11.1 mmol/L) with  symptoms  
of hyperglycemia.[26] 
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CLINICAL CLASSIFICATION 
Classicaly,  the  clinical  presentation  of  Diabetes  was  the  basis  of  
its  classification into  insulin  dependent  and  non  insulin  dependent  
diabetes.  Insulin  dependent diabetes  term  was  used  to  refer  an  early  
onset  diabetes  ( affecting  children  and adolescents  and  adults  < 30  years  
of  age ,  affected  patients  are  lean  and  thin presenting  with  classical  
osmotic  symptoms  (polyuria,  polydipsia,  weight loss) and are  ketosis  prone  
and  requiring  insulin  i.e.,insulin  was  needed  to  prevent  ketosis for  their  
survival. 
Similarly, non insulin  dependent  diabetes  refers  to  adult onset 
diabetes  (>40 years age) ,  in  overweight / obese  individuals  who  were  not  
insulin  requiring  but  were insulin  resistant  and  could  be  controlled  on  
diet,  exercise  and  medications  in combination  or  alone.  However  at  the  
turn  of  the  twenty  first  century  this nomenclature  was  replaced  and  
diabetes  was  classified  into  type 1  and  type 2 diabetes,  this  indicated  a  
paradigm  shift  in  the  basis  of  classification  from  a clinical  basis  to  
pathogenetic basis.
PATHOGENIC CLASSIFICATION 
Type  1  diabetes  mellitus  referring  to  immune  destruction  of  pancreatic  
islets etiology  and  type 2  diabetes  referring  to  non immune  etiology  were  
enunciated. 
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Diabetes  can  be  classified  into  four  clinical  categories: 
1. Type 1  diabetes  (due  to  beta  cell  destruction, usually  leading  to  
absolute  insulin  deficiency) 
- immune mediated 
- idiopathic 
2. Type 2 diabetes ( due  to  a  progressive  insulin  secretory  defect  on  
the background  of  insulin  deficiency) 
3. Other  specific  types  of  diabetes  due  to  other  causes  
Genetic  defects  in  beta  cell  function 
MODY 1- Mutation  in  Hepatocyte  nuclear  transcription  factor                   
                 (HNF) 4 alpha. 
MODY 2  Mutation  in  Glucokinase  gene 
 
MODY 3  Mutation  in  HNF  1 alpha 
 
MODY 4  Mutation  in  Insulin  promoter  factor-1 gene 
MODY 5  Mutation  in  HNF  1D gene 
MODY 6 Mutation in neurogenic differentiation -1 transcription 
factor                    
                  (Neuro D1/Beta 2) 
Mitochondrial  deoxyribonucleic  acid  
Subunits  of  ATP  sensitive  potassium  channel 
Mutations  in  Proinsulin  or  insulin 
Genetic  defects  in  insulin  action 
      Type  A  insulin  resistance 
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      Leprechaunism 
     Rabson  Mendelhall  syndrome 
     Lipodystrophy  syndromes 
Diseases  of  the  exocrine  pancreas:  
Cystic fibrosis,  chronic pancreatitis,  pancreatectomy,  hemochromatosis,  
neoplasia, fibrocalculous pancreatopathy,  mutations in carboxy esteryl lipase. 
Endocrinopathies:  
Acromegaly,   glucoganoma,  pheochromocytoma,  
hyperthyroidism,  somatostatinoma,  aldosteronoma. 
Drug  or  chemical induced : 
 Such  as  in  the  treatment  of  HIV / AIDS  or  after  organ  transplantation 
,viz., glucocorticoids,  pentamidine,  protease inhibitors,  nicotinic acid,  
diazoxide, epinephrine,  beta  adrenergic  agonists,  thiazides,  hydantoin,  
asparaginase, antipsychotics, etc., 
Infections:                                                                                                                     
Congenital  rubella, cytomegalovirus, coxsackie virus                                            
Uncommon  forms  of  immune  mediated  diabetes:                                                               
Stiff  person  syndrome,  insulin  receptor  antibodies 
Other  genetic  syndromes  sometimes  associated  with  diabetes:                                
 syndrome,   syndrome,    syndrome, 
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syndrome,  ataxia,    chorea,  Laurence  moon  biedl  
syndrome,  myotonic dystrophy,  porphyria,  Prader willi syndrome. 
4. Gestational  diabetes  mellitus 
ETIOLOGY AND RISK FACTORS: 
Diabetes  both  type 1  or  type 2  has  equally  strong  genetic  and  
environmental  risk factors  an  interaction  of  which  leads  to  clinical  
expression  of  the  disease. The genetic  suscepitibilty  for  type 1  is  
associated  with  certain  Human  leucocyte  antigen (HLA ) combinations  
DR3, DR4  and  the  environmental  insults  are  rather  ill  defined.  Possibilty  
of  some  aspects  of  diet  and  viral  infections  trigerring  an autoimmune  
exposure  causing  specific  destruction  of  beta  cells  of  pancreas  has been 
proposed. 
Type 2  Diabetes  mellitus  has  a  more  complex  etiopathology. 
Though  it  has  strong genetic  basis  as  shown  by  its  hereditary  nature,  the  
major  suscepitibilty  genes  have  not  yet  been  identified.  Racial  
predisposition  as  seen  in  Asian  population  is also  common . The  
environmental  factors  showing  strong  association  with  diabetes are  
increasing  age,  family  history  of  diabetes,  obesity,  unhealthy  diet, physical 
inacitivity,  insulin  resistance,  adverse  intrauterine,  environmental  and  
stress  factors. 
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PATHOPHYSIOLOGY 
In  Type  1  diabetes  there  is  autoimmune  destruction  pancreatic  
islet  cells following  interaction  between  environmental  and  genetic  factors. 
The  major antibodies  detected  are  insulin  autoantibody,  glutamic  acid  
decarboxylase autoantibody,  insulinoma  associated  autoantigen 2  
autoantibody  and  zinc  transporter 8  autoantibody.  Indeed,  immunological  
studies  revealed  the  essential  involvement  of  the  adaptive  immune  system  
in  the  pathogenesis  of  T1DM. It  is  found  that CD8+ T  cells  are  the  most  
predominant  in  the  insulitis  lesion,  followed  by  CD68+ macrophages,  
CD4+ T cells,  CD20+  B lymphocytes  and  CD138+ plasma cells.  
Figure 1. Pathophysiology of Type 1 DM 
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 The  pathophysiology  of  type  2  diabetes  includes  impaired  insulin  
secretion, impaired  insulin  action,  insulin  resistance  and  impaired  incretin  
effect  on  the  beta cell  function  and  non suppression  of  the  action  of  
alpha  cells  with  rising  blood glucose  levels.  In  the  last  two  decades  the  
role  of  adipokines  as  regulators  of  beta  cell  function  and  insulin  
sensitivity  has  been  demonstrated  in  number  of studies. 
Type 2  Diabetes  is  a  life  style  disorder  and  an  interaction  of  
genetic  and environmental  factors  precipitates  the  metabolic  abnormalities  
existing  in  prediabetic  subjects  to  the  clinical  stage  of  diabetes.  There  is  
a  long  asymptomatic pre-diabetic  stage  before  the  development  of  
diabetes. These  stages  are  easily identifiable  by  OGTT. 
For  the  development  of  diabetes  both  the  basic  pathophysiological  
defects ,i.e., insulin  resistance  and  beta  cell  secretory  defect  have  to  
coexist.    
Figure 2 
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PRE DIABETES 
The  definition  of  IGT  has  been  stable.  The  American  Diabetes  
Association recommends  the  normal  cut  off  for  fasting  plasma  glucose  as  
<100mg/dl.  Both IGT  and  IFG  have  heterogenous  pathogenesis  and  hence  
may  have  different  rates of  progression  to  diabetes. People  with  combined  
IFG  and  IGT  have  approximately double  the  rate  of  conversion  to  
diabetes  than  those  with  any  one  of  the abnormalities. Both  the  states  are  
associated  with  insulin  resistance  and  other cardiovascular  risk  factors  
such  as  dyslipidemia  and  hypertension.  IGT  is  shown  to be  stronger  
predictor  than  IFG.  
Figure 3 
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CLINICAL FEATURES 
The  clinical  features  depend  upon  the  type  of  Diabetes,  the  stage  
in  the  natural history  of  diabetes  and  on  the  presence  of  its  attendant  
complications  or comorbidities. Type 1 diabetes  constitutes  <5%  of  all  
diabetes  while  Type 2  diabetes contributes  to  95%  of  diabetes  in  the  
world  including  in  India.  Type 1  diabetes results  in  near  total  destruction  
of  beta  cells  of  islets  of  Langerhans  in  the pancreas  resulting  in  absolute  
insulin  deficiency  resulting  in  hyperglycemia  which presents  with  osmotic  
symptoms  like  polyuria,  polydipsia  and  unexplained  weight loss  and  with  
diabetic  ketoacidosis  and  intercurrent  infections. 
Type 2  Diabetes  due  to  environmental  and  genetic  factors  result  in  
insulin resistance  ( relative insulin deficiency).  Hyperinsulinemia  in  initial  
stages  keeps fasting  plasma  glucose  normal  but  in  response  to  glucose  
load,  post  prandial hyperglycemia  occurs.  During  the  period  of  worsening  
insulin  resistance  there  will be  loss  of  first  phase  insulin  release  followed  
by  hyperglycemia  in  both  fasting and  post  prandial  state. This  continued  
hyperglycemia  will  result  in  both microvascular  and  macrovascular  
complication  after  a  variable  period  of asymptomatic  phase. 
LATENT AUTOIMMUNE DIABETES OF ADULTS (LADA) 
It  is  a  peculiar  type  of  diabetes  of  adults  wherein  patients  harbor  
autoantibodies  to  islet  cells  as  seen  in  type 1  diabetes,  but  it  occurs  in  
adults  and  is phenotypically  similar  to  type 2  diabetes  i.e., somewhere  
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between  type 1  and  type 2 diabetes.   Age of onset   30years,  no  insulin  
requirement  for  at  least  6  months  after diagnosis  and  presence  of  one  or  
more  of  the  antibodies  (anti-GAD, IAA OR ICA) are  the  criteria  for  
diagnosis  of  LADA.  Latent  autoimmune  diabetes  of  adults in  turn  has  
been  classified  into  LADA  type 1  and  LADA  type 2. 
The  LADA  type 1  has  two  or  more  antibodies  present  in  high  
titres  and  has  a phenotype  closer  to  one  described  for  classical  type 1  
diabetes.  On  the  contrary, LADA  type 2  has  only  one  antibody  present  in  
low  titres  and  the  phenotype  is similar  to  that  for  type  2  diabetes. 
MODY 
Maturity  onset  diabetes  of  Young  is  diabetes  with  a  monogenic  
inheritance  pattern. It  has  a  autosomal  dominant  inheritance  and  has  early  
age  of  onset  and the  genetic  defect  results  in  diminished  insulin  
secretion.  Any  person with  diabetes in  three  successive  generations  with  
the  age  of  diabetes  < 25 years  without  any classical  features  of  insulin  
resistance  should  be  suspected  to  have  MODY. 
  Diabetes  mellitus  can  come  to  our  notice  with  one  or  more  of  the  
following clinical  features: 
 Asymptomatically  diagnosed  on  routine  screening  in  health  camps 
or preventive  health  check  ups. 
 Noticing  ants  in  the  toilet  after  urination  because  of  melituria-  
sweet  urine 
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 Unexplained  weight  loss  despite  normal  appetite 
 Recurrent  bacterial  skin  infection - boils,  carbuncles,  cellulitis 
 Recurrent  urinary  tract  infections 
 Recurrent  or  difficult  to  treat  fungal  infections  of  skin  and  its  
appendages  tinea  corporis / pedis / cruris / candidial  intertrigo  or  
paronychia. 
 Chronic  vaginal  discharge  or  vulval  pruritis  in  females  and  
recurrent balanoposthitis  in  males. 
 Tuberculosis  diabetics  with  uncontrolled  hyperglycemia  have  a  
greater predisposition  to  develop  tuberculosis 
 Polyuria  and  polydipsia 
 Overt  renal  failure  or  microalbuminuria  (diabetic  nephropathy) 
 Diabetic  neuropathy  symmetrical  peripheral  neuropathy  or  other  
variants Impotence,  loss of libido,  dyspareunia  and  loss  of  
sudomotor  functions secondary  to  autonomic  dysfunction 
 Vision  disturbances  rapidly  changing  glasses  because  of  osmotic  
changes  in the  lens  secondary  to  glycemic  fluctuations, early  onset  
cataract,  secondary glaucoma  and  diabetic  retinopathy. 
 Atherosclerotic  vascular  disease  coronary,  cerebral  or  peripheral  
vascular disease 
 Acute  complications  diabetic  ketoacidosis  and  non ketotic  
hyperosmolar  state. 
 
38 
 
RISK FACTORS TO SCREEN 
Risk factors for diabetes which mandates screening in asymptomatic adult 
individual: 
O the following features: 
Physical inactivity 
Diabetes in first degree relative 
History of gestational diabetes mellitus or gave birth to a baby weighing >4kg 
Hypertension (BP  140/90mmHg) 
High density Lipoprotein cholesterol <35mg/dl 
Serum triglycerides >250mg/dl 
High risk ethic groups like pima Indians or races 
Pre diabetes 
Women with polycystic ovarian syndrome 
Clinical conditions associated with insulin resistance  severe obesity, 
acanthosis nigricans 
History of cardiovascular disease and age >45 years 
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COMPLICATIONS 
Unlike  the  microvascular  disease,  which  starts  with  the  onset  of  
diabetes, the macrovascular  disease  antedates  the  development  of  overt  
diabetes  by  several  years.  Around  75%  to  80%  of  all  diabetic  patients  
will  die  prematurely  of cardiovascular  (macrovascular)  disease,  particularly  
coronary  heart  disease. Diabetic foot  problems  (gangrene,  large  non  
healing  infected  ulcers)  are  the  commonest cause  of  non  traumatic  lower  
limb  amputation.  In  one  Indian  study  done  at Chennai,  the  prevalence  of  
coronary  heart  disease  was  21.4%  among  diabetic patients, 14.9%  among  
impaired  glucose  tolerance  subjects  and  11%  among  non diabetic  patients.  
The  prevalence  of  peripheral  arterial  disease  in  the  same population  was  
6.3%. 
There  is  a  close  relationship  existing  between  prediabetes,  Diabetes  
and macrovscular  disease  throughout  life  and  the  substantial  body  of  
evidence  supports the  concept  that  increased  morbidity  and  mortality  due  
to  cardiovascular  disease  is associated  with  abnormalities  in  glucose  
metabolism  across  the  entire  continuum  of glucose  intolerance   ranging  
from  normal  to  clinical  diabetes.  While  the  interplay between  diabetes  
and  cardiovascular  disease  has  been  recognized  for  many  decades,  recent  
data  analysis  of  the existing studies  has  helped  to  redefine  several aspects  
of  the  relationship  with  relevance  to  clinical  practice. 
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Meta analysis  and  systemic  reviews  have  confirmed  that  DM  
increases  CVD  risk by  around  two  fold  on  an  average and  this  risk  is  
subject   to wide variation being lowest  in  the  newly  diagnosed  and  highest  
in  those  with  existing vascular disease, proteinuria or  renal disease. 
Figure 4 
 
The  effects  of  diabetes  on  pathogenesis  of  atherosclerosis  is  due  to  
endothelial  dysfunction,  oxidative  stress, activation  of  polyol  pathways,  
metabolic factors, coagulation  and  inflammatory  factors  and  vascular  
related  factors. 
Chronic  microvascular  complications  of  diabetes mellitus are 
retinopathy, neuropathy, and  nephropathy.  Three  fourth  of  cases  develop  
retinopathy  after  more  than  15 years  of  diabetes,  half  the  diabetics  have  
neuropathy  and  one  third  have nephropathy  in  larger  population study  in  
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US.  Poor  glycemic  control, long  duration of  diabetes  and systolic blood 
pressure are risk factors for microvascular complications. 
Risk of  chronic  complication in  type 1  and  2 diabetes  results  from  
chronic hyperglycemia. It  has  been  conclusively  demonstrated  in  type 1  
and type 2  diabetes microvascular  complications  can  be  prevented  or  
delayed  if  chronic  hyperglycemia is  reduced.  Other  incompletely  defined  
factors  may  moderately reduce development of  complications.  For  instance,  
some  individuals  never  develop  nephropathy or retinopathy  despite  long  
standing  diabetes  though  they  may  have  similar glycemic  control  to  
patients  with  microvascular  complications  suggesting  genetic suscepitibilty  
for  developing  particular compications. 
There  is  now  strong  correlation  between  the  occurrence  and 
severity  of  microvascular  complications  in  both  type  1  and type  2  with  
duration  and  degree  of  hyperglycemia.  Glucose  appears  to damage  tissues  
by  acute  reversible  changes  in  metabolism  (e.g. sorbitol  accumulation,  
increased  NADH/NAD+  ratio,  decreased myoinositol,  early  glycation)  and  
by  cumulative,  irreversible alterations  in  stable  macromolecules  forming  
advanced  end  glycation  products.  Genetic  susceptibility  and  other  
accelerating factors  such  as  hypertension  and  hyperlipidemia,  smoking  also  
play a role. 
Hyperglycemia  causes  increase  in  intracellular  glucose  in  insulin 
independent  tissue  like  nerves,  lens,  retina,  glomerulus. In  these tissues  
glucose  is  converted  by  aldose  reductase  to  sugar alcohol, sorbitol. In  
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many  tissues  it  is  subsequently  oxidixed  to fructose  with  the  help  of  
sorbitol  dehydrogenase  with  NAD+  as cofactor.  This  sorbitol  does  not  
cross  the  cell  membrane  easily  and gets  accumulated  intracellularly.  It  
causes  damage  to  the  tissues through  its  osmotic  effects,  by  increasing  
NADH/NAD+  ratio inducing  pseudohypoxia  and  by  depleting  intracellular  
myoinositol.   
  Myoinositol  is  structurally  related  to  glucose and it  helps  in 
activating  Na+ - K+- ATPase  for  maintaining  nerve  conduction. Its  
depletion  leads  to  impaired  nerve  function  in  diabetes.  
In  other  tissues  hyperglycemia  leads  to  de  novo  synthesis  of  
diacylglycerol  and  activation  of  the  enzyme  protein  kinase C. Protein kinse 
c pathway is a family of serine threonine kinase that change the transcription of 
genes for fibronectin, type 4 collagen,  contractile  proteins  and  extracellular  
matrix  protein  in  endothelial  cells and  neurons. 
This  enzyme  is  implicated  in  several  process  causing  diabetic 
complications  such  as  increased  capillary  permeability  and  contractility,  
blood flow,  cellular proliferation,  basement  membrane thickening.  Protein  
kinase c  mediates  TGF-   angiotensin 2  and  vascular  endothelial  growth  
factor  and  modulates  mitogen activated  protein  kinase  which  mediates  
sclerosis.  Inhibitors  of  PKC   like ruboxistuarin  mesylate  that  reduce  the  
direct  cellular  actions  of  AGES,  VEGF, endothelin-1  reduce  oxidized  
lipids  and  oxidant  production  are  being  studied  in clinical  trials  in  DM  
for  retinopathy  and  neuropathy. 
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Next  is  the  Hexosamine  pathway  where  Fructose  6  phosphate,  a  
substrate  for  O linked  glycosylation  and  proteoglycan  production  is  
generated  through  the hexosamine  pathway  when  hyperglycemia  increase  
the  flux.  Hexosamine  may  alter function  by  glycosylation  of  proteins  such  
as  endothelial  nitric  oxide  synthase  or by  changes  in  gene  expression  of  
TGF-   or  plasminogen  activator  inhibitor-1  (PAI-1). 
With  chronic  hyperglycemia  Amadori  products  in  long lived 
molecules  like  collagen  and  DNA  combine  to  form  cross  linked  
irreversible  structures  called  advanced  end  glycation  products  (AGE).  
Early  non  enzymatic  glycation  products  are  reversible  as  hyperglycemia  
continues  intermediate  poorly  reversible  products  are  formed  and later  
irreversible  AGEs  are  formed.  There  is  a  correlation  between  serum  
levels  of AGEs  and  the  level  of  glycemia;  these  products  accumulate  as  
the  glomerular filtration  rate  declines. 
AGE  accumulation  leads  to  binding  of  LDL  and  other  proteins  to 
collagen  in  blood  vessel  walls  predisposing  to  atherosclerosis  and  
disruption  of  structure  and  impaired  enzymatic  turn  over  of  matrix 
proteins  leading  to  basement  membrane  permeability  and  thickening.  It  
also  causes  endothelial  cells  to  release  cytokines  and  growth  factors  for  
cell  proliferation. 
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DIABETIC RETINOPATHY: 
Diabetic  retinopathy  is  a  disorder  of  the  retinal  vessels  that  
eventually  develops  to some  degree  in  nearly  all  patients  with  long  
standing  diabetes  mellitus.  A  recent study  in  South  India  in  urban  
population  estimates  prevalence  of  DM  in  adult population  as  high  as  
28%  and  the  prevalence  of  DR  in  diabetics as 18%.  Risk factors  for  
diabetic  retinopathy  are  age  at  diagnosis  of  diabetes,  duration,  poor 
control  of  diabetes,  pregnancy,  hypertension,  nephropathy,  hyperlipidemia,  
obesity, anemia,  smoking. 
Hyperglycemia  causes  intracellular  accumulation  of  sorbitol , free  
radical injury, accumulation  of  glycated  end  products,  disruption  of  ion  
channel,  protein  kinase c activation  all  of  which  in  turn  leads  to  direct  
effect  on  retinal  cells,  capillary  wall damage  and  hematological  and  
rheological  changes  that  leads  to  intra retinal hemorrhages,  edema,  
exudates,  microvascular  occlusion  progressing  to  new vessel formation  in  
iris  and  retina  resulting  in  unresolved  vitreous  hemorrhage,  retinal 
detachment,  neovscular  glaucoma  finally  to  blindness. 
     In  diabetic  retinopathy  hemorrheological  disturbances  accompany 
and  sometimes  precede  microangiopathy.  Early  abnormalities  include  
increased  capillary  blood  flow  and  pressure,  increased  blood  viscosity,  
red  cell  aggregation  and  hypersensitivity  of  platelets  to  aggregating  
agents.  This  increased  pressure  causes tangential  shear  forces  on  
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endothelium  resulting  in  stimulation  of  basement  membrane  formation  
and  leading  to  hyperfiltration  of  fluid  out  of  the  capillary. This  later on  
leads  to  capillary  thickening  (sclerosis)  limiting  vasodilatation. 
Figure 5 
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Growth factors: 
Growth  factors  seem  to  play  an  important  role  in  DM  related  
complications  and an  increase  is  seen  in  their  production  by  most  of  
these  proposed pathways. Vascular  Endothelial  Growth  factor   A  is  
increased  locally  in  diabetic  proliferative  retinopathy  and  decreases  after  
laser  photocoagulation.  Inhibition  of angiotensin 2  also  reduces  VEGF,  
which  could  explain  one  of  the  beneficial  effects  of  angiotensin 2  
receptor  blockers  on  microangiopathic  diseases. 
Monoclonal  antibodies  to  VEGF  like  Ranizumab  in  experimental  
studies  have shown  improvement  in  proliferative  diabetic  retinopathy.  An  
increase  in transforming  growth  factor   in  diabetic  nephropathy  
stimulates  basement membrane  production  of  collagen  and  fibronectin  by  
mesangial  cells. Other  growth factors  like  platelet  derived  growth  facror,  
Epidermal  growth  factor,  insulin like growth  factor,  growth  hormone,  basic  
fibroblast  like  growth  factor,  connective tissue  growth  factor  and  even  
insulin  have  been  suggested  to  play  a  role  in  DM related  like  
complications. 
Angiotensin 2: 
The  renin  angiotensin  in  the  kidney  is  abnormally  activated  in  
diabetes.  Angiotensin  directly  binds  to  receptors  in  renal  cells  and  
induces  matrix  deposition in  mesangial  and  tubular  cells  through  TGF-   
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Angiotensin  2  stimulates  VEGF production  in  mesangial  cells  and  impairs  
glomerular  structure  and function.  Similar  changes  are  observed  in  retina.  
STAGES OF DIABETIC RETINOPATHY: 
Figure 6 
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According  to  Early  Treatment  Diabetic  Retinopathy  Study  (ETDRS),  
levels  of diabetic  retinopathy  are 
Figure 7 
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NON PROLIFERATIVE DIABETIC RETINOPATHY 
 
                                                            Figure 8 
SEVERE PROLIFERATIVE DIABETIC RETINOPATHY 
 
Figure 9 
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VERY  SEVERE  NON  PROLIFERATIVE  DIABETIC  
RETINOPATHY 
 
Figure 10 
PROLIFERATIVE  DIABETIC  RETINOPATHY 
 
Figure 11 
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NPDR & PDR: 
 
Figure 12 
CLINICALLY  SIGNIFICANT  MACULAR  EDEMA 
(any  one  of  the  following) 
 Thickening  of  the  retina  located  500µm  or  less  from  the  centre  of  
the macula. 
 Hard  exudates  at  500µm  or  less  from  the  centre  of  the  macula  
with thickening  of  the  adjacent  retina.  
 A  zone  of  retinal  thickening,  one  disc  or  larger  in  size,  any  
portion  of which  is  one  disc  diameter  or  less  from  the  centre  of  
macula. 
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                                                  Figure 13 
 Diabetic  eye  disease  primarily  affects  the  retinal  blood  vessels, but  
diabetes  also  accelerates  cataract  formation.  The  lesions  of diabetic  
retinopathy  can  be  grouped  into  five  categories  according to  the  features  
seen  on  ophthalmoscopy-  background,   preproliferative   and  proliferative  
retinopathy,  advanced  diabetic eye  disease  and  maculopathy. 
BACKGROUND RETINOPATHY: 
Background  retinopathy  is  the  first  stage  of  retinopathy  and  is  not 
associated  with  visual  loss  unless  the  macula  becomes  involved  
(maculopathy).  Early  subclinical  abnormalities  of  the  blood  vessels  are  
basement  membrane  thickening,  loss  of  pericytes  (contractile  cells  which  
control  vessel  caliber  and  flow)  and  increased  blood flow  and  capillary  
permeability.  Microaneursyms  are  the  earliest clinical  sign  of  retinopathy  
and  appear  as  red  dots.  They  are  blind out  pouchings  of  the  capillaries  
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either  at  weakened  points  or  a revascularization  response  to  microvascular  
occlusion. 
Hard  exudates  are  off  white  /  yellow  flakes  or  plaques  of  plasma  
protein  and  lipid  which  have  leaked  from  retinal  blood vessels.  They  are  
more  significant  in  the  area  of  macula.   
Various  forms  of  intraretinal  hemorrhage  also  occur  in  the 
background  retinopathy (superficial  flame  shaped  or  deep  dot  and  blot  
cluster  hemorrhage).  Cotton  wool  spots  are  whitish  elevations  of  the  
nerve  fibre  layer  due  to  intracellular  accumulation of  axoplasmic  material  
in  areas  of  microvascular  occlusion. 
PRE PROLIFERATIVE RETINOPATHY: 
Preproliferative  retinopathy  is  due  to  worsening  retinal  ischemia  
and  carries  a  high  risk  of  developing  into  sight  threatening proliferative  
retinopathy.  Early  referral  to  a  specialist ophthalmologist  is  required.  
Preproliferative  changes  include multiple  cotton   wool  spots  (> 5),  
multiple  hemorrhages,  venous beading  and  intraretinal  microvascular  
abnormalities  (IRMAs,  abnormally   branched  vessels  in  the  retina,  
representing attempts  to  revascularise  the  ischaemic  retina). 
PROLIFERTIVE RETINOPATHY: 
Proliferative  retinopathy  is  marked  by  abnormal  new  vessels 
stimulated  by  growth  factors  released  from  the  ischaemic  retina. These  
new  vessels  grow  forward  towards  the  vitreous  and  overlie the  retinal  
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vessels.  Contraction  of  the  vitreous  gel  causes  hemorrhage  into  the  
vitreous  or  the space  between  the  gel  and  the retina.  New  vessels  on  the  
optic  disk  are  associated  with  the  most  severe  retinal  ischaemia  and  the  
worst  visual  prognosis  but neovascularization  also  occurs  elsewhere  on  
the  retina. 
 
                                                  Figure 14 
ADVANCED DIABETIC EYE DISEASE: 
Advanced  diabetic  eye  disease  comprises  retinal  detachment  or  
tears,  with  preretinal  (boat  shaped)  or  vitreous  hemorrhages  which occur  
when  further  vitreous  contraction  pulls  on  strong  fibrous adhesions  
connecting  the  retina  and  vitreous.  Sight  can  also  be threatened  by  
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glaucoma  due  to  neovascular  tissue  on  the  iris (rubeosis  iridis)  spreading   
peripherally  on  the  pupil  and   obstructing  the  drainage  of  aqueos  humour. 
MACULOPATHY: 
Maculopathy  is  due  to  retinal  edema  and  thickening  close  to 
macula  thus  threatening  or  causing  loss  of  central  vision.  Focal  or  
diffuse  maculopathy  are  caused  by  microvascular  leakage  leading  to  
formation  of   hard  exudates  in  the  area  of  macula.  Ischemic maculpathy  
is  associated  with  areas  of  capillary  non  perfusion and  is  difficult  to 
detect.  Hard  exudates  often  occur  in  rings  (circinate exudates)  around  the  
leaking  area. 
CATARACT: 
Cataract  is  a  common  cause  of  blindness  in  diabetic  patients.  It  is 
recognized  as  an  opacity  against  the  red  fundal  reflex  when  the eye  is  
examined  with  an  opthalmoscope  at  a  distance  of  30cm.  Non  enzymatic  
glycation  of  lens  protein,  especially  alpha  crystalline  and  subsequent  
cross  linking  probably  contributes.  Also sorbitol  accumulation  in  the  
diabetic  also  could  lead  to  osmotic swelling  but  the  evidence  for  this  
mechanisms  in  human  is  less strong  than  in  experimental  diabetic  
cataracts  in  other  species. 
Diabetic  retinopathy  is  the  leading  cause  of  blindness  in  the 
working  population.  The  prevalence  of  retinopathy  increases  with  duration  
of  diabetes  with  few  patients  presenting  with  retinopathy   in  the  first  5  
56 
 
years  of  diabetes  and  80  100%  developing  some  form  of  the  
complication  after  more  than  20 years  duration 
Maculopathy  is  the  most  common  in  type  2  diabetes  and  can  be 
associated  with  severe  visual  loss.  Patients  may  present  with  acute  onset  
cobwebs  /  floaters  or complete  obscuration  of  vision  caused  by  vitreous  
hemorrhage  from  new  vessels growing  into  the  retina  or  optic  disc.  The 
vitreous hemorrhage may absorb spontaneously  over  the  next  few  days  /  
weeks  but  it  is  often  complicated  by recurrent  attacks  of  fresh  
hemorrhage.  The  accompanying  scar  tissue  may  contract leading  to  retinal  
tearing  resulting  in  combined  rhegmatogenous  retinal detachment. Patients  
with  extensive  retinal  ischemia  tend  to  develop  neovascularization  of  the 
iris  and  the  angle  of  anterior  chamber  leading  to  intractable  glaucoma. 
INFLAMMATION AND DIABETES: 
Some  studies  defined  a  clear  cut  relation  between  systemic 
inflammation  and  insulin  resistance  in  Type  2  diabetes  mellitus suggesting  
that   altered  immune  system  plays  a  decisive  role in  the  pathogenesis  of  
DM.  Due  to  increased  delivery  of  glucose to  adipose  tissue  in  DM,  
endothelial  cells  in  the  fat  pad  may take  up  increasing  amounts  of  
glucose  through  their  constitutive glucose  transporters.  Increased  glucose  
uptake  by  endothelial cells  in  hyperglycemic  conditions  causes  excess  
production  of  ROS  in  mitochondria,  which  inflicts  oxidative  damage  and  
activates  inflammatory  signaling  cascades  inside  endothelial  cells. 
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Endothelial  injury  in  the  adipose  tissue  might  attract  inflammatory 
cells  such  as  macrophages  to  this  site  and  further  exacerbate  the  local  
inflammation.  Hyperglycemia  also  stimulates  ROS  production in  
adipocytes,  which  leads  to  increased  production  of  proinflammatory  
cytokines.  
Studies   have  proposed  that  hyperglycemia  can  lead  to  an   
excessive  oxidation    reaction  in  the  tricarboxylic  acid  cycle  leading  to  an  
increase  in  the  generation  of  reactive  oxygen  species (ROS).  As  a  result,  
mitochondrial  function  is  impaired  during  the  production  of  ROS.  Studies  
have  reported  that  leukocytes  in  subjects with  diabetes  mellitus  generates  
more  ROS,  resulting  in  elevated  oxidative  DNA  damage  of  lymphocytes  
in  the  hyperglycemic state.  
Insulin   exerts  its  action  through  binding  to  its  receptor  on  the  
surface  of   insulin-responsive  cells.  The  stimulated  insulin  receptor  
phosphorylates  itself  and  several  substrates,  including  members  of the  
insulin  receptor  substrate  (IRS)  family,  thus  initiating  downstream  
signaling  events.  The  inhibition  of  signaling  downstream  of  the  insulin  
receptor  is  a  primary  mechanism  through  which  inflammatory  signaling  
leads  to  insulin  resistance.  
Exposure  of  cells  to  TNF-   or  elevated  levels  of  free  fatty  acids 
stimulates  inhibitory  phosphorylation  of  serine  residues  of  IRS-1. This  
phosphorylation  reduces  both  tyrosine  phosphorylation  of  IRS-1  in  
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response  to  insulin  and  the  ability  of  IRS-1  to  associate with  the  insulin  
receptor  and  thereby  inhibits  downstream  signaling and  insulin  action. 
Hence,  it  has  become  clear  that  inflammatory  signaling  pathways  
can  also  become  activated  by  metabolic  stresses  originating  from inside  
the  cell  as  well  as  by  extracellular  signaling  molecules.  It  has  been  
demonstrated  that  obesity  overloads  the  functional capacity  of  the  ER  and  
that  this  ER  stress  leads  to  the  activation  of  inflammatory  signaling  
pathways  and  thus  contributes  to  insulin resistance.  Additionally,  increased  
glucose  metabolism  can  lead  to  a  rise  in  mitochondrial  production  of  
ROS.  ROS  production  is elevated  in  obesity,  which  causes  enhanced  
activation  of inflammatory  pathways. 
Several  serine  /  threonine  kinases  are  activated  by  inflammatory  or  
stressful  stimuli  and  contribute  to  inhibition  of  insulin signaling, including  
JNK,  inhibitor  of  NF-  kinase  (NKK).  Again,  the activation  of  these  
kinases  in  obesity  highlights  the  overlap  of  metabolic  and  immune  
pathways.  Inflammatory  cytokine  stimulation  can  also  lead  to  induction  
of  iNOS.  Overproduction  of  nitric  oxide  also  appears  to  contribute  to  
impairment  of  both  muscle  cell  insulin  action  and   cell  function  in  
obesity.  Deletion  of  iNOS   prevents  impairment  of  insulin  signaling  in  
muscle  caused  by  a high-fat  diet.  Thus,  induction  of  such  proteins  and  
iNOS  represent two  additional  and  potentially  important  mechanisms  that  
contribute to  cytokine-mediated  insulin  resistance.  It  is  likely  that  
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additional mechanisms  linking  inflammation  with  insulin  resistance  remain  
to  be  uncovered.  
 
Figure 15. Inflammation and Diabetes 
 
The  role  of  lipids  in  metabolic  disease  is complex.  As  discussed 
above,  hyperlipidemia  leads  to  increased  uptake  of  fatty  acids  by muscle  
cells  and  production  of  fatty  acid  metabolites  that  stimulate inflammatory 
state.  In  patients  with  diabetes,  several  studies  explored  connection  
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between  systemic  inflammation  and  vascular  disease  and  found  that  
chronic  inflammation  promotes  the  development  and  acceleration  of  
microvascular  and  macrovascular  complications. 
Many  inflammatory  markers  have  been  found  to  be  related  to  DM,  
such  as  interleukin-1  (IL1),  IL6,  IL8,  transforming  growth  factor beta  1,  
Tumor  necrosis  factor- alpha  (TNF-
measurement  is  not  used  routinely  as  it  is  not  easy  to  do  it.  Total  white  
blood  cell  (TWBC)  count  is  a  crude  but  sensitive  indicator  of  
inflammation  which  can  be  done  easily in  laboratory  routinely.  It  is  a  
cost-effective  investigation.  Besides  WBC  counts,  the Platelet  Lymphocyte  
Ratio  (PLR),  Monocyte  Lymphocyte  Ratio  (MLR),  and  Neutrophil  
Lymphocyte  Ratio  (NLR)  are  potential  biomarkers  reflecting  inflammation  
and  immune responses.  Many  studies  have  reported  positive  correlations  
of  conventional  inflammatory  markers  with  the  PLR  and NLR.  
NEUTROPHIL  LYMPHOCYTE  RATIO: 
More  importantly,  a  large  number  of  studies  found  predictive 
effects  of  the  PLR  and  NLR,  particularly  in  DM[15  18].  The  
neutrophil-lymphocyte  ratio  (NLR)  in  complete  blood  count  is  studied  in  
many diseases as  an  inflammatory  marker  and  is  used  to  predict the  
prognosis  of  diseases.  Interestingly,  NLR  has  been  found  to have  a  
positive  corelation  with   metabolic  syndrome.  
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  A study by Imtiaz et al.  has  suggested  that  chronic  diseases  such  as 
hypertension  and  diabetes  have  a  significant  association  with systemic  
inflammation,  reflected  by  NLR.  
Shiny et al. have  shown  that  NLR  is  correlated  with  increasing 
severity  of  glucose  intolerance  and  insulin  resistance  and  can be  used  as  
a  prognostic  marker  for  macro-  and  micro-vascular complications  in  
patients  with  glucose  intolerance.  Initially,  NLR  was  recognized  as  a  
predictive  marker  in  multiple  types  of  cancer that  might  assist  in  patient  
stratification  and  individual  risk . In  this  respect,  NLR  has  emerged  as  a  
novel  surrogate  marker. 
The  immune  response  to  various  physiological  challenges  is 
characterized  by  increased  neutrophil  and  decreased  lymphocyte counts,  
and  NLR  is  often  recognized  as  an inflammatory  marker to  assess  the  
severity  of  the  disease.  NLR  represents  a combination  of  two  markers  
where  neutrophils  represent  the active  nonspecific  inflammatory  mediator  
initiating  the  first  line of  defense,  whereas  lymphocytes  represent  the  
regulatory  or  protective  component  of  inflammation.   But  recently,  
multiple  other  studies  have  indicated  that  NLR  might  be  a predictive  
marker  for  vascular  diseases  also. Recently,  several studies  have  suggested  
that  NLR  could  play  a  predictive  role  for  assessing  the  development  of  
microvascular  complications  of diabetes.  
 In  a  study,  Ulu et al. [17] demonstrated  NLR  to  be  a  quick  and  
reliable  prognostic  marker  for  diabetic  retinopathy  and  its  severity. 
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 A  study  conducted  in  geriatric  population  also  suggested  that  
increased  NLR  levels  were  in  itself  an  independent  predictor  for  
microvascular  complications  of  DM[36].  The  exact  molecular  action 
leading  to  IR  is  not  yet  understood,  but  several  studies  have confirmed  
NLR  is  superior  to  other  leukocyte  parameters  (e.g., neutrophil,  
lymphocyte,  and  total  leukocyte  counts)  because  of  its better  stability  
compared  with  the  other  parameters  that  can  be altered  by  various  
physiological,  pathological,  and  physical  factors. Thus,  as  a  simple  
clinical  indicator  of  IR,  NLR  is  more  sensitive  compared  with  the  
neutrophilic  granulocyte  count  and  CRP  levels.  
PLATELET  LYMPHOCYTE  RATIO: 
Some  angiogenesis  factors  such  as  vascular  endothelial  growth 
factor  (VEGF)  are  key  protein  modulators  expressed  by  platelets.  
Notably,  high  VEGF  levels  can  stimulate  the  development  of  proliferative  
diabetic  retinopathy  (PDR)[38].  This  would  suggest  that  there  is  
association  between  the  PLR  and  DR  progression.  Data  generated  from  
research  has  supported  a  close  association  of  systemic  inflammatory  
processes  with  oxidative  stress,  leading  to alterations  of  platelet  and  
lymphocyte  levels. Thus,  the  underlying mechanism  of  up-regulated  PLR  
may  also  be  based  on  the  dysfunction  of  the inflammatory  response. 
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MONOCYTE  LYMPHOCYTE  RATIO: 
Monocytes  are  considered  as  a  biomarker  for  inflammation  because  
their  activation  leads  to  the  synthesis  of  inflammatory  cytokines.  A  
previous  report  suggested  that  monocytes  may  be  relevant  to  angiogenic  
processes  in atherosclerosis[39].  Nevertheless,  the  mechanisms  underlying  
the  association  between  the  MLR  and  DR  should  be  investigated  in  
future  studies. 
All  the  people  with  DM  (type 1  or  Type 2)  are  at  risk. .The  longer  
the  person  has diabetes  the  higher  the  risk  of  developing  DR.  Early  
detection,  education  and research  are  the  key  to  prevent  visual  
impairment  /  blindness  from  DR. Ophthalmoscopy  is  the  most  commonly  
used  technique  to  screen  for  DR.  It  is critical  to  identify  patients  who  
are  in  immediate  need  of  treatment  with  laser photocoagulation. 
Regular  examination  of  the  eyes  in  diabetic  patients  for  early 
detection  of  retinopathy  is  essential  and  should  include  visual acuity  
measurement  with  a  snellen  chart  and  examination  of  the fundus  through  
dilated  pupils.  When  the  retina  cannot  be  seen  because  of  cataract  or  
hemorrhage,  the  patient  should  be  referred  to  an  ophthalmologist. Yearly  
examinations  are  recommended  for those  with  no  retinopathy,  6  monthly  
for  those  with  background retinopathy  and  referral  to  an ophthalmologist  
for  cataract ,  maculopthy,  increasing  hemorrhages. ,  proliferative  and  
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preproliferative  changes,  marked  fall  in  acuity,  retinal detachment,  vitreous  
hemorrhage  and  rubeosis  iridis. 
Blindness  due  to  retinopathy  can  be  caused  by  maculopathy,  
vitreous  hemorrhage,  retinal  detachment  and  neovascular  glaucoma  but  
visual  loss  can  now  be  largely  prevented  by  laser  photocoagulation  and  
vitreoretinal  surgery.  Panretinal photocoagulation  commonly  with  an  argon  
laser  is  used  to  treat new  vessels  and  preproliferative  retinopathy.  The  
whole  retina  is partially  ablated  except  for  the  macula  and  papillomacular  
bundle which  are  essential  for  central  vision.  This  concentrates  the  blood 
supply  on  the  remaining  retina  and  diminishes  the  ischaemic stimulus  to  
new  vessel  formation.  Established  new  vessels  regress and  further  
neovascularization  is  inhibited.  
Laser  photocoagulation  is  also  used  to  treat  maculopathy  focal  or 
grid  (for  diffuse  or  ischaemic  maculopathy)  treatment  seals  points of  
vascular  leakage  reducing  edema  and  deposition  of  hard  exudates.  The  3  
year  risk  of  severe  visual  loss  in  maculopathy  is reduced  by  over  50%  
with  photocoagulation. 
  
65 
 
MATERIALS AND METHODS 
Source of Data: 
        This  study  is  done  in  patients  who  came  to  Coimbatore  Medical  
College   
        Hospital  outpatient  department.  
Study Period: 
       One  year  from  June  2016  to  July  2017. 
Sample size: 
       150 
Study Design: 
      Case  control  study 
SELECTION CRITERIA: 
 Inclusion criteria  
           Patients  of  both  gender  aged  more  than  18  years  of  age  are  
selected. 
 Exclusion criteria 
          Patients with the following comorbidities are excluded 
- Hematological diseases 
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- Hepatic failure 
- Renal failure 
- Cardiac failure 
- Any  acute  or  chronic illness 
- Alcohol abuse 
- Hypertension 
- On  drugs  that  alter  platelet  function 
- Pregnant  women 
- Patients  not  capable  of  giving  consent 
- Patients  who  are  not  willing  to  participate  in  the  study. 
TECHNIQUE: 
This  study  involves  150  diabetes  mellitus  patients.  They  are  
divided  into  three groups. 
Group A  50  patients  with  diabetes  mellitus  as  control  subjects. 
Group B  50  diabetic  patients  with  non - proliferative  diabetic  retinopathy. 
Group C  50  diabetic  patients  with  proliferative  diabetic  retinopathy. 
Cases  and  controls  are  selected  on  the  basis  of  inclusion  and  exclusion  
criteria  in the  study. 
Patients  blood  pressure,  height  and  weight  measurements,  age,  
gender, accompanying  disease  history,  smoking  habits,  treatment  history  
will  be  recorded. 
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PLR,  NLR,  MLR  AND  DIABETIC  RETINOPATHY  DEFINITIONS: 
They  are  calculated  as  ratios  of  platelets,  neutrophils  and  monocytes  to  
lymphocyte  ratio. 
Diabetes  is  diagnosed  by  WHO  criteria. 
Diabetic  retinopathy: 
 NPDR  is  identified  by  the  presence  of  microaneursyms  or  
intraretinal hemorrhages,  hard  and  soft  exudate. 
 PDR  is  identified  by  the  presence  of  neovascularisation  of  optic  
disc  and / or  elsewhere  in  fundus  with  or  without  vitreous  
hemorrhage. 
INVESTIGATION: 
Complete  blood  count  By  using  WBC,  Neutrophil,  Lymphocyte,  
Monocyte, Platelet -  NLR,  MLR,  PLR can be calculated. 
Biochemical  tests  like  plasma  glucose  level,  lipid  profile  and  renal  
parameters, HbA1C  are  done. 
After  getting  clearance  from  ethical  committee  of  Coimbatore  Medical  
college, study  was  done. 
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RESULTS AND ANALYSIS 
The  study  population  consisted  of  150  patients  who  had  fulfilled  
the  inclusion  and exclusion  criteria  and  they  are  divided  into  three  groups  
and  all  of  them  belong  to  type  2  diabetes  mellitus. 
Group A  50  diabetic  patients  without  retinopathy 
Group B  50  diabetic  patients  with  non proliferative  retinopathy 
Group C  50  diabetic  patients  with  proliferative  retinopathy 
The  baseline  characteristics  of  all  groups  were  analysed  and  are  shown  
in  the following  tables  and  bar  diagrams. 
The  mean  value  for  each  parameter  like  Age,  Sex, Duration  of  
DM,  Blood pressure,  Smoking,  Lipid profile,  Fasting blood sugar,  Total 
count, Neutrophils, Lymphocytes,  Monocyte,  Platelet,  NLR,  MLR,  PLR  
were  calculated  and  compared between  groups  and  co related  with  
severity  of  diabetic retinopathy to find out the significance. 
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Table 1. Group wise distribution 
GROUP NO OF PATIENTS PERCENTAGE 
T2DM 50 33.33% 
T2DM+NPDR 50 33.33% 
T2DM+PDR 50 33.33% 
 
                                             Chart 1. Group wise distribution 
 
The  overall  age  distribution  of  the  study  population  and  age  distribution  
in  each group  is  shown  in  the below  table  and  chart. 
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                                          AGE DISTRIBUTION 
Table 2.  Age distribution in the study 
 
AGE (IN YEARS) NO OF PATIENTS PERCENTAGE 
< 50 56 37.30% 
51-60 80 53.30% 
> 60 14 9.40% 
 
Chart 2. Age distribution in the study 
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Table 3.  Group wise Age distribution 
GROUP 
AGE (IN YEARS) T2DM T2DM+NPDR T2DM+PDR 
< 50 26 23 7 
51-60 22 24 34 
> 60 2 3 9 
 
Chart 3. Group wise Age distribution 
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Table 4. Sex distribution in the study 
 
SEX NO OF PATIENTS PERCENTAGE 
MALE 75 50.00% 
FEMALE 75 50.00% 
                            
Chart 4. Sex distribution in the study 
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Table 5. Group wise sex distribution in the study 
GROUP 
SEX T2DM T2DM+NPDR T2DM+PDR 
MALE 21 29 25 
FEMALE 29 21 25 
 
Chart 5. Group wise sex distribution in the study 
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                          Table 6. Smoking distribution in the study 
SMOKING NO OF PATIENTS PERCENTAGE 
PRESENT 53 35.30% 
ABSENT 97 64.70% 
                            
Chart 6. Smoking distribution in the study 
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Table 7. Group wise smoking distribution in the study 
GROUP 
SMOKING T2DM T2DM+NPDR T2DM+PDR 
PRESENT 14 21 18 
ABSENT 36 29 32 
 
Chart 7. Group wise smoking distribution in the study 
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                       Table 8 . Duration of  Diabetes mellitus 
DURATION NO OF PATIENTS PERCENTAGE 
< 5 YEARS 77 51.30% 
5-10 YEARS 49 32.60% 
> 10 YEARS 24 16.10% 
 
Chart 8. Duration of diabetes mellitus 
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Table 9. Group wise duration of diabetes mellitus 
GROUP 
DURATION T2DM T2DM+NPDR T2DM+PDR 
< 5 YEARS 48 27 2 
5-10 YEARS 2 23 24 
> 10 YEARS 0 0 24 
 
Chart 8. Group wise duration of diabetes mellitus 
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Table 10. Mean of Age, Systolic BP, Diastolic BP 
GENERAL CHARECTERISTICS (N = 150) 
FACTOR MEAN SD 
AGE (YRS) 52.92 6.99 
SYSTOLIC BP 136.53 18.5 
DIASTOLIC BP 87.07 13.87 
 
Chart 10. Mean of Age, Systolic BP, Diastolic BP 
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Table 11. Mean of Duration of DM, Fasting blood sugar,HbA1c 
GENERAL CHARECTERISTICS (N = 150)  DM 
FACTOR MEAN SD 
DURATION OF DM(YRS) 6.26 4.18 
FBS 163.26 35.26 
HBA1C 8.29 1.17 
 
Chart 11. Mean of  Duration  of  DM, Fasting  blood  sugar, HbA1c 
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Table 12. General characteristics of Total cholesterol, Triglycerides, HDL 
GENERAL CHARECTERISTICS (N = 150)  LIPID 
FACTOR MEAN SD 
TOTAL CHOLESTEROL 223.13 24.15 
TRIGLYCERIDES 179.35 20.12 
HDL 41.37 13.87 
 
Chart 12. General characteristics of Total cholesterol, Triglycerides, HDL 
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                Table 13. General characteristics of complete blood count 
GENERAL CHARECTERISTICS (N = 150)  BLOOD 
FACTOR MEAN SD 
WBC 6359.13 1350.49 
LYMPHOCYTE 2316.96 558.68 
NEUTROPHIL 2992.17 811.71 
MONOCYTE 409.88 158.3 
PLATELET 230633 61546 
 
          Table 14. General characteristics of NLR, MLR. PLR 
GENERAL CHARECTERISTICS (N = 150)  RATIO 
FACTOR MEAN SD 
NEUTROPHIL/LYMPHOCYTE 1.3 0.13 
MONOCYTE/LYMPHOCYTE 0.17 0.04 
PLATELET/LYMPHOCYTE 99.98 13.79 
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             Table 15. Comparison of means of age in different groups 
GROUP 
AGE (IN YEARS) 
MEAN SD 
T2DM 50.28 8.06 
T2DM+NPDR 51.76 5.33 
T2DM+PDR 56.72 5.68 
P VALUE - 0.001 
SIGNIFICANT 
ANOVA 
 
Chart 13. Comparison of means of Age in different groups 
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Table 16. Mean duration of DM 
GROUP 
DURATION OF DM IN YRS 
MEAN SD 
T2DM 2.48 1.98 
T2DM+NPDR 5.68 2.27 
T2DM+PDR 10.66 3.34 
P VALUE - 0.001 
SIGNIFICANT 
ANOVA 
 
Chart 14. Mean duration of DM 
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                       Table 17. Mean systolic BP in three groups 
GROUP 
SYSTOLIC BP 
MEAN SD 
T2DM 128 12.4 
T2DM+NPDR 137.4 18.6 
T2DM+PDR 144.2 19.5 
P VALUE - 0.001 
SIGNIFICANT 
ANOVA 
 
Chart 15 .Mean systolic BP in three groups 
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Table 18. Mean diastolic BP in three groups 
GROUP 
DIASTOLIC BP 
MEAN SD 
T2DM 84.4 10 
T2DM+NPDR 86.4 12.2 
T2DM+PDR 90.4 17.49 
P VALUE - 0.001 
SIGNIFICANT 
ANOVA 
 
                          Chart 16 . Mean diastolic BP in three groups 
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Table 19. Mean fasting blood sugar in three groups 
GROUP 
FASTING BLOOD SUGAR 
MEAN SD 
T2DM 137.46 15.6 
T2DM+NPDR 166.06 33.7 
T2DM+PDR 186.26 34.22 
P VALUE - 0.001 
SIGNIFICANT 
ANOVA 
 
Chart 17.Mean diastolic blood pressure in three groups 
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Table 20. Comparison of mean HbA1c in  three groups 
GROUP 
HBA1C 
MEAN SD 
T2DM 7.46 0.64 
T2DM+NPDR 8.09 0.84 
T2DM+PDR 9.13 1.25 
P VALUE - 0.001 
SIGNIFICANT 
ANOVA 
 
Chart 18. Comparison of mean HbA1c in all three groups 
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Table 21. Comparison of Total cholesterol in three groups 
GROUP 
TOTAL CHOLESTEROL 
MEAN SD 
T2DM 213.5 20.49 
T2DM+NPDR 219.08 18.08 
T2DM+PDR 236.25 26.99 
P VALUE - 0.001 
SIGNIFICANT 
ANOVA 
 
Chart 19. Comparison of mean chlolesterol in all three groups 
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Table 22. Comparison of mean triglycerides in three groups 
GROUP 
TRIGLYCERIDES 
MEAN SD 
T2DM 169.32 20.6 
T2DM+NPDR 182.06 19.2 
T2DM+PDR 186.68 16.8 
P VALUE - 0.001 
SIGNIFICANT 
ANOVA 
 
Chart 20. Comparison of mean triglycerides in three groups 
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Table 23. Comparison of mean HDL in three groups 
GROUP 
HIGH DENSITY LIPOPROTEIN 
MEAN SD 
T2DM 43.4 8.28 
T2DM+NPDR 42.48 9.28 
T2DM+PDR 37.72 6.18 
P VALUE - 0.001 
SIGNIFICANT 
ANOVA 
 
Chart 21. Comparison of mean HDL in three groups 
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Table 24. Comparison of mean WBC in three groups 
GROUP 
WHITE BLOOD CELLS 
MEAN SD 
T2DM 6042 1017 
T2DM+NPDR 6546 1425 
T2DM+PDR 6490 1496 
P VALUE - 0.119 
NON SIGNIFICANT 
ANOVA 
 
                      Chart 22. Comparison of mean WBC in three groups               
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     Table 25.Comparison of mean Lymphocyte count in three groups 
GROUP 
LYMPHOCYTES 
MEAN SD 
T2DM 2363.2 417 
T2DM+NPDR 2342.8 611.52 
T2DM+PDR 2250.9 876 
P VALUE - 0.567 
NON SIGNIFICANT 
ANOVA 
 
Chart 23.Comparison of mean lymphocyte count in three groups 
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Table 26. Comparison of mean neutrophil count in three groups 
GROUP 
NEUTROPHIL 
MEAN SD 
T2DM 2824.1 631 
T2DM+NPDR 3011.8 886 
T2DM+PDR 3140 876 
P VALUE - 0.146 
NON SIGNIFICANT 
ANOVA 
 
Chart 24. Comparison of mean neutrophil count in three groups 
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Table 27  . Comparison of mean monocyte count in three groups 
GROUP 
MONOCYTE 
MEAN SD 
T2DM 334.1 113.69 
T2DM+NPDR 442.1 158.4 
T2DM+PDR 453.44 171.2 
P VALUE - 0.002 
SIGNIFICANT 
ANOVA 
 
Chart 25. Comparison of mean monocyte count in three groups 
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              Table 28. Comparison of mean platelet count in three groups 
GROUP 
PLATELET 
MEAN SD 
T2DM 211840 29983 
T2DM+NPDR 236798 67227 
T2DM+PDR 243327 74332 
P VALUE - 0.025 
SIGNIFICANT 
ANOVA 
 
Chart 26. Comparison of mean platelet count in three groups 
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Table 29.Comparison of NLR in three groups 
GROUP 
NEUTROPHIL/LYMPHOCYTE 
MEAN SD 
T2DM 1.17 0.1 
T2DM+NPDR 1.32 0.08 
T2DM+PDR 1.42 0.08 
P VALUE - 0.002 
SIGNIFICANT 
ANOVA 
 
Chart 27. Comparison of NLR in three groups 
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Table 30. Comparison of MLR in three groups 
GROUP 
MONOCYTE/LYMPHOCYTE 
MEAN SD 
T2DM 0.13 0.02 
T2DM+NPDR 0.19 0.03 
T2DM+PDR 0.195 0.04 
P VALUE - 0.001 
SIGNIFICANT 
ANOVA 
 
Chart 28. Comparison of MLR in three groups 
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Table 31. Comparison of PLR in three groups 
GROUP 
PLATELET/LYMPHOCYTE 
MEAN SD 
T2DM 91.73 17.29 
T2DM+NPDR 102.01 9.31 
T2DM+PDR 106.72 8.97 
P VALUE - 0.001 
SIGNIFICANT 
ANOVA 
 
Chart 29. Comparison of PLR in three groups 
 
91.73
102.01
106.72
80
85
90
95
100
105
110
T2DM T2DM+NPDR T2DM+PDR
MEAN PLATELET / LYMPHOCYTE
99 
 
PEARSON CORRELATION WITH RETINOPATHY 
FACTORS R VALUE P VALUE 
AGE IN YEARS 0.377 0.001 
DURATION OF DM 0.065 0.427 
SYSTOLIC BP 0.801 0.001 
DIASTOLIC BP 0.339 0.029 
FASTING BLOOD SUGAR 0.178 0.001 
HBA1C 0.567 0.001 
TOTAL CHOLESTEROL 0.586 0.466 
TRIGLYCERIDES 0.068 0.001 
HDL 0.395 0.001 
WBC 0.353 0.001 
LYMPHOCYTE 0.278 0.095 
NEUTROPHIL 0.137 0.316 
MONOCYTE 0.082 0.051 
PLATELET 0.16 0.042 
NEUTROPHIL/LYMPHOCYTE 0.736 0.001 
MONOCYTE/LYMPHOCYTE 0.52 0.001 
PLATELET/LYMPHOCYTE 0.43 0.001 
P VALUE < 0.05 IS SIGNIFICANT AT 95% CI 
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DISCUSSION 
 
Diabetic  retinopathy  is  a  microvascular  complication  of  diabetes  
involving  series  of multiple events. Powell et al., has  reported  that  some  
anti inflammatory  agents  may prevent  the  disease  occurrence,  showing  that  
inflammation  play  a  role  in  diabetic retinopathy  pathogenesis.[27] 
Lutty et al., verified  the  association  between  WBCs  and  Diabetic  
retinopathy occurrence[28].  Besides  WBC  count  there  are  some  novel  and  
potential  inflammatory markers  like  Neutrophil  Lymphocyte  ratio,  
Monocyte  lymphocyte  ratio,  Platelet Lymphocyte  ratio  has  a  positive  
correlation  with  occurrence  and  severity  of diabetic  retinopathy. There  are  
many  number  of  studies  which  has  found  the predictive  effects  of  these  
ratios  in  picking  up  cases  with  diabetic  retinopathy. 
In  this  study,  factors  like  age,  duration  of  diabetes,  smoking,  
fasting  blood  sugar, HbA1C,  lipid profile,  NLR,  PLR,  MLR  were  assessed  
and  compared  between  all the  three  groups  to  know  the  predictive  effects  
of  the  above  mentioned  factors  in finding  out  the  earlier  occurrence  of  
Diabetic  retinopathy. 
In  this  study  majority  of  them  53.3%  lie  in  the  age  group  of  51  
60  years.  Sex distribution  was  equal.  NPDR  is  seen  in  many  of  male  
patients,  whereas  PDR  is found  equally  in  both  the  sexes.  Smoking  was  
present  in  35%  of  subjects, showing  that  majority  are  non smokers.  
Among  the  three  groups,  NPDR  had  the maximum  smoking  population  of  
21  subjects. 
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Majority  of  people  around  51.2%  had  duration  of  diabetes  less  
than  5 years. Comparison  of  means  by  using  Anova  test  showed  
significant  corelation  with  age  and  duration  of  DM.  As  the  duration  of   
DM  increases,  progression  of  diabetic retinopathy  worsens. 
Blood  pressure,  fasting  blood  sugar,  lipid  profile  has  a  significant  
co relation  with a  P value  of  <0.001.  HbA1c  showed  significance  by  
using  Anova  test.  The  rate  of progression  of  diabetic  retinopathy  
increases  with  the  increase  in  mean  HbA1c. 
The  mean  WBC,  Lymphocyte,  Neutrophil  did  not  show  any  
relation  with  diabetic retinopathy  whereas  monocyte  and  platelet  showed  
significant  relation.  All  the  three  ratio  NLR,  MLR,  PLR  showed  a  
significant  relation  by  using  Anova. 
By  using  Pearson  correlation,  age, blood pressure,  fasting blood 
sugar,  HbA1c,  lipid profile,  Total count ,  NLR,  MLR,  PLR  showed  a  
significant  correlation  with  p value  <0.05  at  95%CI.  Thus  by  using  both  
Anova  and  pearson  correlation  there  is a  significant  correlation  between  
the  NLR,  MLR,  PLR  and  diabetic  retinopathy. 
The  advantage  in  using  these  ratio  is  that  they  show  a  good  
stability  because  they are  absolute  counts  which  do  not  vary  much  with  
alteration  in physiological, physical  and  pathological  factors.  Our  results  
suggest  that  DM  patients  with  DR  had  higher  ratios  compared  to  
diabetics  without  DR.  This  is  in  accordance  with findings  seen  in  similar  
study  conducted  by  Ulu et al.[17]  and  Wang et al.[18] 
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CONCLUSION 
In conclusion,  the  NLR,  MLR,  PLR  ratios  are  significantly  
increased  in  the  setting of  diabetic  retinopathy  and  they  also  correlate  
well  with  the  severity  of  diabetic retinopathy.  Thus  early  detection  of  
these  abnormal  ratio  levels  will  be  helpful  to detect  diabetic  retinopathy  
and  also  to  assess  the  progression  of  the  disease  in diabetic  patients 
Hence,  these  ratios  can  serve  as  remarkable  markers  while  
evaluating  diabetes patients  with  or  without  retinopathy  and  they  are  of  
predictive  and  prognostic value.  These  are  all  simple,  fast,  non invasive  
and  widely  available  inflammatory biomarkers  that  can  offer  an  additional  
information  to  stratify  the  risk  and  to assess  the  severity  of  diabetic  
retinopathy  progression. 
Further  studies  should  be  done  to  establish  the  normality  value  for  
these  ratios  for  specific  population  and  should  be  designed  to  assess  the  
effectiveness  of  anti inflammatory  therapies  using  the  fall  of  the  ratios  as  
a  surrogate  outcome  and assess  its  role  in  guiding  treatment. 
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ANNEXURE 1 
CASE PROFOMA 
NAME  
AGE / SEX                                                                      ADDRESS 
OCCUPATION                                                               OP NO 
HISTORY OF PRESENTING ILLNESS 
PAST HISTORY 
PERSONAL HISTORY 
VITALS 
GENERAL EXAMINATION  
SYSTEMIC EXAMINATION 
FUNDUS EXAMINATION 
INVESTIGATIONS: 
CBC  Hemoglobin, Total count, absolute lymphocyte, neutrophil , monocyte 
count, platelet count, NLR, MLR, PLR. 
FBS 
LIPID PROFILE                                                                                                                
HbA1C 
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                                                       ANNEXURE  2 
 
                                                    CONSENT FORM 
 
 
be a participant  in  the  ASSOCIATION 
BETWEEN DIABETIC  RETINOPATHY  AND  THE  
NEUTROPHIL  LYMPHOCYTE RATIO, PLATELET 
LYMPHOCYTE RATIO, MONOCYTE LYMPHOCYTE RATIO  
in CMC Hospital, Coimbatore, conducted by DR.KIRUTHIKA J., Post 
Graduate Student, Department of General Medicine, Coimbatore  Medical 
College. You are eligible after looking into the inclusion criteria. You  
can  ask  any  question  you  may  have  before  agreeing  to  participate. 
 
TOPIC OF RESEARCH  
 
ASSOCIATION BETWEEN DIABETIC  RETINOPATHY  AND  
THE  NEUTROPHIL  LYMPHOCYTE RATIO, PLATELET 
LYMPHOCYTE RATIO, MONOCYTE LYMPHOCYTE RATIO  
 
PURPOSE OF RESEARCH 
In  this  study, interventions  that  are  both  cost  saving  and  feasible  in 
developing  countries  like  complete  hemogram  are  used  to  screen  for 
complication  of  diabetes  like  Diabetic  retinopathy. 
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PROCEDURES INVOLVED IN THE STUDY: 
- Fetching  baseline  characteristics  of  the  patient  like  age, gender, 
height, weight, etc., 
- Properly  elicited  medical  history  pertaining  to  the    
complaints 
- Detailed  general  and  systemic  examination  as  guided  by  the  
medical history 
- Blood,  urine  and  fundus  examination  as  guided  by  the  clinical  
examination 
- Treatment  with  standard  protocol  currently  followed  in  our  
hospital. 
- Continued  follow  up  of  patient. 
- Recording  all  the  above  variants / events  into  the  database  and  
analyzing them  by  statistical  methods  to  arrive  at  our  objectives. 
 
DECLINE FROM PARTICIPATION 
 
You  are  hereby  made  aware  that  participation  in  this  study  is  
purely  voluntary and honorary,  and that you  have  all the  rights  to 
decline from participating in it. 
 
PRIVACY AND CONFIDENTIALITY 
Privacy of individuals will be respected and any information about you or 
provided by you during the study will be kept strictly confidential. 
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AUTHORIZATION TO PUBLISH RESULTS   
 
Results of the study may be published for scientific purposes and/or 
presented to scientific groups, however you will not be identified.          
    
STATEMENT OF CONSENT 
I volunteer and consent to participate in this study. I have read the consent 
or it has been read to me. The study has been fully explained to me, and I 
may ask questions at any time. 
 
-------------------------------                           -------------------------------   
Signature /Left thumb impression                       Date 
(volunteer)   
--------------------------------                          -------------------------------- 
Signature of witness                                               Date 
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